Nepsis Inc’s Jazz Pharmaceuticals JAZZ Stock Holding History

Nepsis Inc’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-82,606	Closed	-$13.2M	–	31
2022 Q4	$13.2M	Buy	+82,606	New	+$12.1M	4.41%	9

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nepsis Inc's JAZZ Position: Q1 2023 in Review

Nepsis Inc sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 82,606 shares — an estimated $13.2M sold.

Nepsis Inc first reported a position in JAZZ in Q4 2022 and held it in 1 quarter. The position peaked at $13.2M in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Nepsis Inc reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Nepsis Inc sold 82,606 Jazz Pharmaceuticals shares in Q1 2023, an estimated $13.2M.
Nepsis Inc first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Nepsis Inc's Jazz Pharmaceuticals position peaked at $13.2M in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Nepsis Inc's 13F filing for Q1 2023, filed 14 Apr 2023.